Kondrup Maria, Raunkilde Louise, Svane Inge Marie, Schmidt Henrik, Bastholt Lars
Ugeskr Laeger. 2017 Oct 2;179(40).
Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors - anti-cytotoxic T-lymphocyte-associated-4 antibodies and anti-program-med cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque-lae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.
在过去几年里，我们使用免疫检查点抑制剂——抗细胞毒性T淋巴细胞相关蛋白4抗体和抗程序性细胞死亡蛋白1/抗程序性细胞死亡配体1抗体治疗了更多类型的癌症。在治疗过程中可能会出现一组独特的副作用，称为免疫相关不良事件（irAEs）。尽管严重的irAEs仍然很少见，但可能会危及生命。因此，早期发现irAEs并启动相关治疗对于降低长期后遗症的风险至关重要。我们根据既定指南提供了irAEs的详细概述和治疗建议。
